Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated With maribavir

Journal of Infectious Diseases

Volumn 202, Issue 1, 2010, Pages 104-108

  Strasfeld, Lynns ^a   Lee, Ingi ^c   Tatarowicz, Walter ^d   Villano, Stephen ^d   Chou, Sunwen ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ViroPharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; RIBONUCLEOSIDE;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETINITIS; VIREMIA; VIRUS ISOLATION; VIRUS LOAD; VIRUS SHEDDING; CYTOMEGALOVIRUS; DISEASE TRANSMISSION; DRUG EFFECT; GENETICS; HEART TRANSPLANTATION; LUNG TRANSPLANTATION; MUTATION; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEART TRANSPLANTATION; HUMANS; LUNG TRANSPLANTATION; MALE; MUTATION; RIBONUCLEOSIDES; VIRAL LOAD; VIREMIA;

EID: 77953714487     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653122     Document Type: Article

References (15)

1. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005;49:873-883. (Pubitemid 40327699)
2. Scott GM, Weinberg A, Rawlinson WD and Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007; 51:89-94. (Pubitemid 46047692)
3. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002;46:2365-2372.
4. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virusinfected subjects. Antimicrob Agents Chemother 2003;47:1334-1342. (Pubitemid 36368594)
5. Lalezari JP, Aberg JA, Wang LH, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002;46:2969-2976.
6. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebocontrolled, dose-ranging study. Blood 2008; 111:5403-5410.
7. Avery RK, Marty FM, Strasteld L, et al. Oral maribavir for treatment of resistant or refractory cytomegalovirus infections in transplant recipients [abstract V-1256]. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 14 September, 2009. Washington, DC: American Society for Microbiology, 2009.
8. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008; 18:233-246. (Pubitemid 352018847)
9. Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob Agents Chemother 2009;53:81-85.
10. Landry ML, Stanat S, Biron K, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 2000; 44:688-692. (Pubitemid 30117962)
11. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004;34:1071-1075. (Pubitemid 40028840)
12. Hamprecht K, Eckle T, Prix L, Faul C, Einsele H, Jahn G. Ganciclovirresistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of'phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 2003; 187:139-143. (Pubitemid 36034483)
13. Chou S, Van Wechel LC, Marousek GI. Effect of cell culture conditions on the anti-cytomegalovirus activity of maribavir. Antimicrob Agents Chemother 2006;50:2557-2559. (Pubitemid 43993205)
14. Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 2009; 19:215-229.
15. Chou S, Marousek GI. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 2006;50:3470-3472. (Pubitemid 44527529)